Korea:314130

Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab

* The first microbiome oncology therapeutic candidate developed by an Asia -based biotech successfully initiatesphase 1/1b clinical trial in the US, six months after its IND went into effect.  * The first patient enrolled and treated at OHSU (Oregon Health & Science University Knight Cancer In...

2020-10-27 21:00 629

Genome & Company receives FDA IND clearance for GEN-001, its first anti-cancer microbiome therapeutic

SEOUL, South Korea, April 20, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130), a biotechnology company developing innovative therapeutics in immune-oncology, announced today thatthe United States (US) Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) applic...

2020-04-20 14:41 1142

Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

SEOUL, South Korea, Jan. 14, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt,Germany and Pfizer Inc. to evaluate the safety, tolerability, biological and clinical ...

2020-01-14 08:00 919